2BBBullish & Bearish
Health Care

NeoGenomics, Inc. (NEO) Stock Score & Signals

NeoGenomics, Inc. (NEO) trades on NASDAQ. It operates in the Health Care sector, Diagnostics & Research industry. Its current 2BB score is 50 out of 100.

About NeoGenomics, Inc.

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.

2BB score and signals

NeoGenomics, Inc.’s current 2BB score is 50 out of 100, built from the signal categories below.

SignalScoreReading
Activity66High
Momentum48Stable
Financial strength44Normal
Quality100Very Strong
Risk36Low

Company facts

CEOChristopher M. Smith
HeadquartersFort Myers, Florida, United States
Founded2002
Employees2.5K
52-week range$5.94 – $16.92

Recent earnings

Report dateEPS actualEPS estimateRevenue actualRevenue estimate
2027-02-150.0696$212.07M
2026-10-260.054$207.94M
2026-07-280.0331$198.97M
2026-04-280.010.0072$186.67M$186.35M